March 16th 2023
Kidney Cancer Association president Gretchen Vaughan discusses improvements being rolled out by the organization and the importance of multidisciplinary care.
Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
Oncology Town Hall™: Primary Investigators Present Key Abstracts in Genitourinary Malignancies from Paris
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
Show Me Your Care Plan! Developing Multidisciplinary Strategies to Optimize the First-Line Care of Patients with mRCC
Medical Crossfire®: Key Questions on Sequencing, Radioligands, and Novel Emerging Approaches in CRPC
How Guidelines and Recent Clinical Trial Data Inform the Modern-Day Treatment of Advanced Prostate Cancer
Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future
Cases and Conversations™: How The Experts Make Evidence-Based Treatment Decisions in Castration-Resistant Prostate Cancer
Addressing Racial and Ethnic Disparities in Breast Cancer Care: Improving Outcomes Across the Spectrum of Diagnosis, Trial Access, and Patient Care
Lenvatinib/Pembrolizumab Combo Improved Efficacy Over Sunitinib Across RCC Risk GroupsJune 9th 2021
Lenvatinib plus pembrolizumab was efficacious for patients with advanced renal cell carcinoma and performed well in subgroup analyses of International Metastatic Renal Cell Carcinoma Database Consortium risk categories and target kidney lesions.
Adjusting for Subsequent Therapy Reveals Trend Toward OS Benefit With Lenvatinib Plus Everolimus in RCCJune 9th 2021
A post hoc analysis of the CLEAR trial shows that patients may derive an overall survival benefit with lenvatinib plus everolimus versus sunitinib for frontline treatment of RCC, with efficacy ongoing.
HRQOL Analysis From CLEAR Trial Further Support Pembrolizumab/Lenvatinib Combo for Frontline RCCJune 7th 2021
Across 3 health-related quality of life scales, the combination of pembrolizumab plus lenvatinib had similar or better outcomes than sunitinib for patients with metastatic renal cell carcinoma receiving treatment in the frontline.
Viktor Grünwald, MD, PhD, on CLEAR Trial Subgroup Analyses of Pembrolizumab/Lenvatinib in RCCJune 5th 2021
CancerNetwork® sat down with Viktor Grünwald, MD, PhD, at the 2021 ASCO Annual Meeting to talk about how new data from the CLEAR trial serve to further inform clinicians about lenvatinib and pembrolizumab for first-line renal cell carcinoma.
Prolonged Duration of Response With Tivozanib for RCC Revealed at Long-Term Follow-UpJune 4th 2021
Follow-up data from the phase 3 TIVO-3 trial that were reported at the 2021 ASCO Annual Meeting serve to further support the use of tivozanib versus standard-of-care sorafenib in patients with metastatic renal cell carcinoma who have failed on prior therapy.
Hand-Foot Skin Reaction Secondary to Sunitinib in a Patient With Metastatic Clear Cell Renal Cell Carcinoma
Another installment of Clinical Quandaries is presented by Karen Férez-Blando, MD, and colleagues of a 45-year-old man with a diagnosis of intermediate-risk stage IV clear cell renal carcinoma who develops grade 2 hand-foot skin reaction on sunitinib therapy.
Pembrolizumab Plus Lenvatinib Earns Priority Review in 2 Disease IndicationsMay 6th 2021
In the advanced treatment setting, an FDA decision has indicated that the combination of pembrolizumab and lenvatinib may soon be available for certain patients with endometrial tumors and renal cell carcinoma.
Safety and Efficacy of Investigational Agents Under Evaluation in Umbrella Study for Advanced RCCApril 13th 2021
The safety and efficacy of experimental combinations of investigational agents are being analyzed as treatment for advanced clear cell renal cell carcinoma as part of a phase 1b/2 umbrella platform study.
High BMI Levels Associated With Improved Overall Survival for Patients with mRCC Treated with ICIsMarch 29th 2021
Data from JAMA Oncology concluded that patients with a high BMI treated with PD-1/PD-L1–based immune checkpoint inhibitors for mRCC have higher overall survival rates than those with a low BMI.
Thomas Hutson, DO, PharmD, on the CLEAR Trial and Its Implications for the Treatment of RCC in the Frontline SettingMarch 19th 2021
CancerNetwork® sat down with Thomas Hutson, DO, PharmD, to discuss results of the CLEAR trial presented at the recent Genitourinary Cancers Symposium.
Future Use of Novel Combinations for Metastatic RCC TreatmentMarch 17th 2021
Drs Toni Choueiri and Robert J. Motzer highlight various strategies with novel-based therapies being explored to address limitations surrounding the treatment of metastatic renal cell carcinoma.
Risk Scoring Systems for Metastatic RCCMarch 17th 2021
Considerations regarding the value of using the IMDC (International Metastatic Renal Cell Carcinoma Database Consortium) criteria to risk-stratify patients with metastatic renal cell carcinoma as novel therapies become more widely used.
Implications for Treating Metastatic RCC With TKI/I-O Regimens UpfrontMarch 17th 2021
Recommendations regarding how to use novel combinations such as lenvatinib and everolimus, or lenvatinib plus pembrolizumab as frontline therapy for metastatic renal cell carcinoma.
The Phase 3 CLEAR Study in Metastatic RCCMarch 17th 2021
Robert J. Motzer, MD, of the Memorial Sloan Kettering Cancer Center, discusses the rationale for studying lenvatinib plus pembrolizumab or everolimus for frontline metastatic renal cell carcinoma treatment and reacts to outcomes of the phase 3 CLEAR study as presented at ASCO GU 2021.
Personal Approaches to Frontline Therapy for Metastatic RCCMarch 17th 2021
Drs Toni Choueiri and Robert J. Motzer discuss factors that impact their decisions for treatment of metastatic renal cell carcinoma in the first-line setting and highlight their go-to regimens.
Frontline Combination Approaches for Metastatic RCCMarch 17th 2021
Toni Choueiri, MD, of the Dana-Farber Cancer Institute, comments on the impact of emerging data presented on newer, novel combination therapies as upfront treatment for patients with metastatic renal cell carcinoma.
FDA Grants Priority Review to Belzutifan for von Hippel-Lindau Disease–Associated RCCMarch 16th 2021
The FDA accepted a new drug application for belzutifan to treat von Hippel-Lindau disease¬–associated renal cell carcinoma and granted it priority review based on response rate results from a phase 2 trial.
Tivozanib Receives Full Approval for Treatment of Patients With Third-Line or Later RCCMarch 10th 2021
Based on results of the phase 3 TIVO-3 trial in patients who have previously received at least 2 lines of therapy for renal cell carcinoma, the FDA granted approval to tivozanib for use in this patient population.